FDA
-
-
-
-
-
-
-
Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma
-
-
-
-
-
-
-
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multip
-
-
-
-
-
-
-
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hype
-
-
-
-
-
-
-
Bristol Myers Squibb drug shows promise in adolescent heart trial
-
-
-
-
-
-
-
Iza-bren meets dual endpoints in phase III breast cancer trial
-
-
-
-
-
-
-
Bristol Myers Squibb Teams Up with Kasey Keller to Share His Lymphoma Journey with Breyanzi
-
-
-
-
-
-
-
Bristol Myers receives FDA orphan drug designation for systemic sclerosis
-
334,595 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


